Compare Abbott Laboratories (ABT) vs Remitly Global Inc (RELY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Remitly Global Inc — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Remitly Global Inc trades at $23.07 (market cap $5.08B). The key difference: Abbott Laboratories is far larger — about 32.9× Remitly Global Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals.
| ABT | RELY | |
|---|---|---|
Market Cap | $166.94B | $5.08B |
Sector | Health | Technology |
52-Week High | $136.62 | $24.28 |
52-Week Low | $82.57 | $12.20 |
Enterprise Value | $193.69B | $4.47B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
RELY trades at $24.13, up 1.6% on the day, with strong bullish technical signals from moving averages and a consensus analyst price target of $25.67. The company shows accelerating revenue growth, reaching $1.64 billion in 2025, and has achieved profitability with net income of $67.93 million. Recent news highlights expansion into Canada and new business features driving investor optimism.
Outlook remains positive due to sustained revenue growth and market expansion, though high valuation multiples and overbought RSI levels pose near-term risks. The stock offers growth potential in digital payments but faces execution and competitive pressures in the remittance space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
